Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 2/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27716691 | 0.89 | NOTUM (0.53) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL29808797 | 0.89 | NOTUM (0.76) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL5752612 | 0.89 | NOTUM (0.76) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL2272178 | 0.87 | ELANE (0.56) | NOTUMPOLBELANECYP1A2BRD9 | |
| SCHEMBL8229059 | 0.87 | NOTUM (0.51) | NOTUMELANECYP1A2CFTRBRD9 | |
| SCHEMBL8065166 | 0.86 | NOTUM (0.65) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL561882 | 0.85 | CYP1A2 (0.51) | NOTUMELANECYP1A2BRD9MAPT | |
| SCHEMBL4152306 | 0.84 | NOTUM (0.62) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL560810 | 0.83 | NOTUM (0.61) | NOTUMPOLBELANECYP1A2ALKBH5 | |
| SCHEMBL8063220 | 0.83 | NOTUM (0.61) | NOTUMPOLBELANECYP1A2ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144998-A1 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2017-05-25 | — | — | US | disclosed |
| US-20170144998-A1 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2017-05-25 | — | — | US | disclosed |
| WO-2015200349-A2 | ELASTASE INHIBITORS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-12-30 | — | — | WO | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269872-A1 | NOVEL SALT 628 | ASTRAZENECA AB (SE) | 2012-10-25 | — | — | US | disclosed |
| CN-102639505-A | Pyridin-2-one compounds as inhibitors of neutrophil elastase | ASTRAZENECA AB | 2012-08-15 | — | — | CN | disclosed |
| US-20100216843-A1 | NOVEL SALT 628 | ASTRAZENECA R&D | 2010-08-26 | — | — | US | disclosed |
| US-20100216843-A1 | NOVEL SALT 628 | ASTRAZENECA R&D | 2010-08-26 | — | — | US | disclosed |
| US-20100216843-A1 | NOVEL SALT 628 | ASTRAZENECA R&D | 2010-08-26 | — | — | US | disclosed |
| WO-2010094964-A1 | TOSYLATE SALT OF A 5-PYRAZOLYL-2-PYRIDONE DERIVATIVE, USEFUL IN THE TREATMENT OF COPD | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | WO | disclosed |
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | HANSEN PETER | 2009-05-21 | — | — | US | disclosed |
| WO-2009037413-A1 | DIMERS OF 5- [ (4-CYANOPHENYL) SULFINYL] -6-METHYL-2-OXO-1- [3- (TRIFLUOROMETHYL)PHENYL] -1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE FOR TREATING RESPIRATORY DISEASES | ARGENTA DISCOVERY LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| CN-101142189-A | 2-pyridine derivatives as inhibitors of neutrophile elastase | ASTRAZENECA AB (SE) | 2008-03-12 | — | — | CN | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007107706-A2 | DIMERS OF HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF COPD | ARGENTA DISCOVERY LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269872-A1 | NOVEL SALT 628 | REN, SCN8A, SLC38A7 | NOTUM 1286/4885POLB 2985/4885ELANE 1755/4885 |
| US-20100216843-A1 | NOVEL SALT 628 | REN, SCN8A, SLC38A7 | NOTUM 1275/4885POLB 2558/4885ELANE 2508/4885 |
| US-20090131483-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | NOTUM 2923/4885POLB 1396/4885ELANE 2/4885 |
| US-20170144998-A1 | ELASTASE INHIBITORS | SERPINB1, ELANE, CELA1 | NOTUM 551/4885POLB 463/4885ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.